Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Femasys Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-- INNOVATIVE SINGLE-DEVICE SOLUTION INTEGRATES PROVEN FEMVUE AND FEMCHEC  TECHNOLOGIES TO SUPPORT FALLOPIAN TUBE EVALUATION AND IMPROVE WORKFLOW EFFICIENCY-- ATLANTA, DEC. 18, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED TODAY IT HAS RECEIVED 510(K) CLEARANCE FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS FEMVUE CONTROLLED DEVICE, AN INNOVATIVE DIAGNOSTIC SOLUTION DESIGNED FOR CONTROLLED CONTRAST DELIVERY TO EVALUATE FALLOPIAN TUBE STATUS. THE NEXT-GENERATION FEMVUE CONTROLLED DEVICE INTEGRATES FEATURES OF THE COMPANY'S ORIGINAL FEMVUE AND FEMCHEC TECHNOLOGIES INTO A SINGLE FDA-CLEARED PRODUCT, ENABLING MULTIPLE CLINICAL USES WHILE STREAMLINING MANUFACTURING AND PRACTICE WORKFLOWS.

FEMASYS SECURES U.S. FDA CLEARANCE FOR NEXT-GENERATION FEMVUE DIAGNOSTIC DEVICE

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ:PMCB) (PHARMACYTE OR THE COMPANY), TODAY ANNOUNCED THE SUCCESSFUL MONETIZATION OF ITS STAKE IN FEMASYS INC. (NASDAQ: FEMY), FURTHER VALIDATING THE COMPANY'S STRATEGIC APPROACH TO CAPITAL DEPLOYMENT AND STRENGTHENING ITS ALREADY SOLID FINANCIAL POSITION. FOLLOWING THE MONETIZATION OF THE STAKE, PHARMACYTE'S CASH AND MARKETABLE SECURITIES ARE EXPECTED TO INCREASE TO APPROXIMATELY $20 MILLION, UP FROM $13.3 MILLION AS OF JULY 31, 202.

PHARMACYTE BIOTECH SUCCESSFULLY MONETIZES FEMASYS STAKE, STRENGTHENING CASH POSITION AND UNDERSCORING STRATEGIC CAPITAL DEPLOYMENT

-- SUCCESSFUL COMPLETION OF FIRST TRIAL PHASE ENABLES CONTINUED PIVOTAL TRIAL OF FEMBLOC, THE ONLY NON-SURGICAL PERMANENT BIRTH CONTROL, TOWARD U.S. FDA APPROVAL -- -- $12 MILLION SENIOR SECURED CONVERTIBLE NOTES FOR TOTAL POTENTIAL PROCEEDS OF $58 MILLION, IF ALL WARRANTS ARE EXERCISED FOR CASH, REFLECTING STRONG INVESTOR CONFIDENCE IN FEMASYS' WOMEN'S HEALTH MISSION --

FEMASYS SECURES FDA APPROVAL TO ADVANCE FINAL FEMBLOC TRIAL PHASE AND $12 MILLION FINANCING, WITH POTENTIAL TO REACH $58 MILLION

SAN ANTONIO, TEXAS, OCT. 16, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, IS PLEASED TO ANNOUNCE THAT IT WILL EXHIBIT AT THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM) 2025 SCIENTIFIC CONGRESS & EXPO, WHICH WILL TAKE PLACE OCTOBER 25-29 AT THE HENRY B. GONZLEZ CONVENTION CENTER IN SAN ANTONIO, TEXAS.

FEMASYS TO EXHIBIT AT THE ASRM 2025 SCIENTIFIC CONGRESS & EXPO

-- FOLLOWING THE SETUP KIT, THE INSEMINATION KIT COMPLETES THE SPERM PREPARATION PORTION OF FEMSPERM ENABLING GYNECOLOGY CALL POINT ACTIVATION TO DRIVE REVENUE GROWTH -- -- FOLLOWING THE SETUP KIT, THE INSEMINATION KIT COMPLETES THE SPERM PREPARATION PORTION OF FEMSPERM ENABLING GYNECOLOGY CALL POINT ACTIVATION TO DRIVE REVENUE GROWTH --

FEMASYS EXPANDS FEMSPERM PRODUCT LINE WITH NEW INSEMINATION PREP KIT TO BROADEN GYNECOLOGY-BASED ACCESS TO FEMASEED

ATLANTA, AUG. 25, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY) (THE COMPANY OR FEMASYS), A LEADING BIOMEDICAL INNOVATOR ADDRESSING SIGNIFICANT UNMET NEEDS IN WOMEN'S HEALTH WORLDWIDE, WITH A BROAD PORTFOLIO OF DISRUPTIVE, ACCESSIBLE, IN-OFFICE THERAPEUTIC AND DIAGNOSTIC PRODUCTS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 10,434,586 SHARES OF ITS COMMON STOCK, OR IN LIEU THEREOF, PRE-FUNDED WARRANTS TO PURCHASE UP TO 11,750,000 SHARES OF ITS COMMON STOCK, TOGETHER WITH ACCOMPANYING COMMON WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 22,184,586 SHARES OF ITS COMMON STOCK. THE COMBINED PUBLIC OFFERING PRICE FOR EACH SHARE OF COMMON STOCK AND ACCOMPANYING COMMON WARRANT IS $0.36, EXCEPT FOR 87,363 SHARES AND ACCOMPANYING WARRANTS SOLD TO CERTAIN OFFICERS OF THE COMPANY AT A PRICE OF $0.5151 PER SHARE AND ACCOMPANYING WARRANT. THE COMBINED OFFERING PRICE OF EACH PRE-FUNDED WARRANT AND ACCOMPANYING COMMON WARRANT IS $0.3599. EACH ACCOMPANYING COMMON WARRANT WILL HAVE AN EXERCISE PRICE OF $0.36, EXCEPT FOR THE WARRANTS SOLD TO CERTAIN OFFICERS OF THE COMPANY WHICH WILL HAVE AN EXERCISE PRICE OF $0.5151. EACH OF THE ACCOMPANYING WARRANTS WILL BE IMMEDIATELY EXERCISABLE FROM THE DATE OF ISSUANCE AND WILL EXPIRE FIVE YEARS FROM THE DATE OF ISSUANCE.

FEMASYS ANNOUNCES PRICING OF $8.0 MILLION UNDERWRITTEN PUBLIC OFFERING

-- CONTINUED PROGRESS ON REGULATORY APPROVALS AND GLOBAL COMMERCIALIZATION OF FERTILITY PORTFOLIO -- ATLANTA, AUG. 08, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

FEMASYS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS FOR 2025

--INITIATION OF ACCESS TO FEMBLOC, A REVOLUTIONARY NON-SURGICAL PERMANENT CONTRACEPTIVE, AS GLOBAL AVAILABILITY ACCELERATES-- ATLANTA, AUG. 06, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED ITS FIRST COMMERCIAL ENTRY INTO EUROPE WITH AN ORDER OF APPROXIMATELY $400,000 USD FOR FEMBLOC PERMANENT BIRTH CONTROL IN SPAIN, THE FIRST COUNTRY WITH AN ESTABLISHED DISTRIBUTION PARTNERSHIP.

FEMASYS SECURES FIRST EUROPEAN ORDER FOR FEMBLOC, MARKING STRATEGIC MILESTONE IN GLOBAL EXPANSION

-- MILESTONE EXPANDS GLOBAL REACH AND REINFORCES COMMITMENT TO ACCESSIBLE, FIRST-LINE INFERTILITY SOLUTIONS -- ATLANTA, JULY 01, 2025 (GLOBE NEWSWIRE) -- FEMASYS, INC., (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR ADDRESSING SIGNIFICANT UNMET NEEDS IN WOMEN'S HEALTH WORLDWIDE, WITH A BROAD PORTFOLIO OF DISRUPTIVE, ACCESSIBLE, IN-OFFICE THERAPEUTIC AND DIAGNOSTIC PRODUCTS ANNOUNCES THE ACHIEVEMENT OF REGULATORY APPROVALS IN AUSTRALIA AND NEW ZEALAND FOR ITS NEXT-GENERATION INFERTILITY SOLUTIONS: FEMASEED FOR FIRST-LINE INTRATUBAL INSEMINATION TREATMENT AND FEMVUE FOR DIAGNOSTIC EVALUATION. SECURING REGULATORY APPROVALS IN AUSTRALIA AND NEW ZEALAND MARK ANOTHER IMPORTANT STEP IN EXPANDING GLOBAL ACCESS TO OUR INNOVATIVE INFERTILITY SOLUTIONS, SAID KATHY LEE-SEPSICK, CEO AND FOUNDER OF FEMASYS.

FEMASYS ACHIEVES AUSTRALIAN AND NEW ZEALAND REGULATORY APPROVALS FOR FEMASEED FOR FIRST-LINE INFERTILITY TREATMENT AND FEMVUE DIAGNOSTIC

ATLANTA, JUNE 25, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC., (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR ADDRESSING SIGNIFICANT UNMET NEEDS IN WOMEN'S HEALTH WORLDWIDE, WITH A BROAD PORTFOLIO OF DISRUPTIVE, ACCESSIBLE, IN-OFFICE THERAPEUTIC AND DIAGNOSTIC PRODUCTS, ANNOUNCES CONFORMIT EUROPENE (CE) MARK CERTIFICATION UNDER EUROPEAN UNION MEDICAL DEVICE REGULATION (EU MDR 2017/745) OF THE CLASS III FEMBLOC BLENDED POLYMER COMPONENT, MARKING THE FIRST REGULATORY APPROVAL IN THE WORLD FOR THE FEMBLOC SYSTEM FOR NON-SURGICAL FEMALE PERMANENT BIRTH CONTROL. AFTER EUROPEAN MEDICINES AGENCY (EMA) REVIEW, THE NOTIFIED BODY HAS GRANTED CE MARK CERTIFICATION.

Femasys Inc.

FEMY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Femasys Inc.

FEMY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FEMY